1428 2007

1

)

(Aretaeus 200

. "" "

"Diabetes .

1675 ) (Thomas Willis "

"Mellitus " "

" "

. ,

" "Diabetes Insipidus .

) (Joseph Von Mering

) (Oskar Minkowski 1889

2
 ,

. 1910

- ) (Sir Edward Sharpey - Schafer

"" .

, " "Langerhans

. ) (Bating

1920 .

1922.

, , .

%8-5

. 2006

171 .

2030

, %75 ,

%44 ,

, %30

286

. ,

, , ,

%17.3 %12.18

) .( 2000 ,

%5-4 .

2000
2030

2030 2000
99.000 37.000
6.726.000 2.623.000
2.009.000 668.000
680.000 195.000
319.000 104.000
378.000 146.000
245.000 88.000
1.138.000 427.000
343.000 113.000
88.000 38.000
2.523.000 890.000
331.000 97.000
1.277.000 447.000
2.313.000 627.000
684.000 350.000
1.286.000 327.000
1.203.000 426.000

: 2006.

.( ( WHO,1999

___________________________________________________

5 20

10 20.39

40 40-59

45 60

)(

, , , .

" " ,

" ".

, ,

).( WHO, 1999

)( . ,

,( 2

" " .

) .( Gale and Anderson, 2005

5 "

" .

9
 .

: :

, , .

" " Fructose .

" " Cellulose

" " :

10
 , , ,

" " ,

) ( .

..

11


. .

7-3 .

12


%60 ,

13


) A1c (HbA1c

14


) (

, , .

8 ( 110100/ 3 ) 6.1 /(.

* 110 125 100/ 6.9 6.1) 3 /(

) impaired

( fasting glucose

* 126 100 / 7 ) 3 /(

, ,

180 100 10) 3 /(

15
 ) (Renal Sugar Threshold .

.( ( America Diabetes Association, 2001

100/ ) 3/(
(6.1)110
(6.1-7) 125 -110

) (
* (7 )126

* .

* 126100/ 3

. ,

16
 ,

) ( glucose tolerance test

, .

AIC

17
 * ) (

75

. 30 .

* 75

140100 / 7.80 ) 3 / (

* 75

200-140 100/ 11.1-7.8 ) 3 / (

" "

.((impaired glucose tolerance

* 75

200 100 / 11.1) 3 /( ,

.((American Diabetes Association, 2001

18


75 ) /

100 ) 3/(
(7.80 ) 140
(7.80-11.1) 200 -140

) (
* ) 200 (11.1

) A1c (HbA1c

19
 A1c

. ((Kuzuya etal.,2002

,(glycated haemoglobin . ,

) , , ,

, ( ,

%1

,%12

,%25

. %16

A1c .%6-4

%7

) .( %6 .5

20
 %4 60100 / 3

3 %5 90 100/

3 %6 120 100/

3 %7 150100/

3 %8 180100/

%1 30 100/ . 3

A1c .

A1c

21
 . %25

45

%20 .

) 140/90 (.

) (HDL )

35/( )

250/( ) 2.83/(.

10

22


23


: ) ( Type 1

, ) ( Type 2

24
 , ,

).(American Diabetes Association, 2001

" "1

)) .IDDM

. " " Juvenile diabetes

11

13 , .

( Atkinson and Eisenbarth , 2001) .

) ( Ketoacidosis (Diabetic coma).

25


, ,

, ,

20-10 .

) ( Antibodies

26


. ,

400.

) ,(mumps " Coxsackie

" , ,

27
 %10-5 .

) ( , .

%50 ,

) .( Rennert et al., 1999

, .

, %10-5

. , ,

) (.

28
 .

. .

%8 %45

29
 ,

, " ."BSA

. , ,BSA

BSA .

30


" "2

) . (NIDDM

. " " .

) ( Apple- shape

, .

31


, ,

.(( Tumilehto et al., 2001

) (.

) (% 90

(,Rosenbloom et al. 2001 )American Diabetes Association;2000

2001 85.000 ,

%5

32


. %80 %95

. ,

) )

, , , ,

. ) pear

(shape .

35 ) 89 (

40 ) 102 (

) .( Defronzo, 1997

, ,

. ) ( ,

33


34


) 2.5( . .

0.8 1.0

35


%25 %33

, . ,

36
 , ,

. , ,

. .

19 ,

37


16 .

2000

1998-1990 ) (%70

. .

1999 %6

%10 .

) .( Defronzo, 1997

) ( .

%8 %45

) .

() .( Rosenbloom, 2001

38


,
,
,






20-30%

39
 : )(Secondary

). (Pheochromocytoma

: ) (acromegaly

, ) (Hyperthyroidism

, Cushing's Syndrome

Thyroid hormone

: ) (Gestational Diabetes

40


, .

.1

41
 ,

, .

) .( WHO, 1999

. ,

42
 "" " "

%25

25 .

) 4,5(

43
 135 100 3

25.

.%4

%13

, ,

44
 .

. 2

45


. .1

46
 . .2

, .

, ,

, , .

) (Polydypsia

. .

) (

47


). (Polyuria

))polyphagia

) (

) Glucagone ( ,

48
 .

)( .

) ( Diabetic Ketoacidosis

) (ketoacidosis

49
 .

) ( , .

) (.

50
 .

....

51


52


, .

, , , .

. (Srivastava & Brajendra,2006

53


, .

) , , ,

(.

54
 .

)(.

) (.

55
 .

)( , ,

" "

56
 ,

, ,.

. ..

..

..

57


,,

)( neuropathy

)) (capsaicin

Tricyclic antidepressants

) (amitriptaline ),(doxepin

%75 . ,

,venlafaxine sertraline

) ( Gabapentin

58
 ) ( Tramadol

, , ,.

) (E Vitamin

Erythromycin

Metoclopramide

Sildenafil

%15 .%53

59
 :

, , .

,%60 %25

60


, , .

, , ,,

" "

, .

Statin

,Zocor , Lescol

61


.Fenofibrate

Niacin

%30

62


. 80/120

) (ACE Inhibitors )

,(Captopril ) ,(Enalapril )(isinopril

, .

%30 ,%60

%50

12.000 24.000

63


20 74 .

,retinopathy

Cataract ) )Glucoma

20-15 .

64
 ,

) (macula

) (

) (

65


, .

)( Glucoma

. :

66
 , .

)( , .

" ."glomeruli

67
 . ,

, , ,

:
.

68
 :

)( .

) (

69
 ,

%50

..

70


, ,

71


"" .

72


""*

) (.

30.

* " " :

73
 ) (

%45

.%10 %45

, ,

, .

, ,

74


" " .

) , ,

(.

)(

75
 .

. .

, , ,

76
 ,

, ,

77


78


))

,Alzheimer .

55 .

79


)) .Pneumonia

%5 %15

(Preumococcal pneumonia .

80


, ,

, .

. .

, ,

) (.

Hyperglycemic Keto

acidotic coma

81


acetone acetoacetic

acid . - hydroxybutyric acid

82


. .

83


84


14-7

85
 ,

, ,
,
, ,legs
. ,
,

,

86
 ,
.
leak






,



,leg
,


,
.
,





) ( ,





.

87


88


89
 .

%50

90
 .

, , ,.

..... ..... .....

91


55

, ,

)(

)( ,

, .

92
 65

( ,

93


, ,

94


, ,

20 10 .

95


96
 1966

) (Richard lillehei

28 .

. 1979

1990 .

100 1400

97


55 . %95

)Frank et al.,

.( 2004

98


) (Immunosuppressives

.1

%75 .

99
 ,

.2

%15 .

.3

%10 .

100


%86

, %77 , %70

%81 , %65

, %52 .

7-5

, ,

4-2 .

101
 .

3-1

102
 .

) (.

. ,

103
 . ,

2500

, 1700

. 900

, 600-500

. 50

104
 .

105
 ,

, ,

) (Umbilical vein

(Portal vein .

106


Islet cell autotransplantation

Islet cell

allotransplantation

107


( Berneyy et al., 2002

(.

108


2006 36

, %40

%14

, ,

109
 .

110


1980

111
 ( .

, , ,(.

112
 )

(.

(.

) ( Vials

pre- filled syringes

Cartridge

,recombinant insulin

, , .

113


, , ,

114
 .

Ultra short acting

Insulin

)( )insulin lispro (Humalog

115
 ) ,( insulin aspart (Novolog,

).Novorapid

))

cartridge .

15-5 .

15

, 5-3

116


monomeric

) 5 (

Hexameric

117


45-30 .

)-3

4( ) 8-6(.

Short acting

insulin
118


, ) (Humulin R, Novolin R

, .

30 .

45-30

. 4-2

8-6 .

119


Intermediate acting

insulin

NPH Humulin

N . Novolin N

) (Lente Humulin L

. Novolin L ,

, .

, .

120
 2.5-1 ,

10-4

16 .

%30

%70

12-4

) 18-12( .

121


Long acting

insulin

ultralente )

(Humulin U .

10-6 , 20

, .

Glargine ) (Lantus

24 .

122


24 .

(.

, .

)(

123


2-1 .

30

25 .

6 .

% 4-3 , , , ,

124
 Insulin mixtures

) (NPH

125


%70 %30

30/70 30/70 .

%50 %50

50/50.

126



3-5 30-90 5-15
)(

1-3 )(

2-5 5-8 30-60
) ,
(
14-24 8-14 1-2.5
) ,
(

8-12 1-2.5 ) (

20-36 10-18 4-6
) (

24 1-2 )(
No peak
7-12 30 , 25/75
50/50 , 30/70

127
 .

128


90-45.

, ,

129
 .

130
 .

( 1 Insulin Syringes

131
 , , ,

( 2 Pre filled Insulin

pens

. )(

) 150 300

1.5 3( .

132
 5( 31-29

Humulin, Humalog.

12 .

133


134


( 3 External Insulin Pump

. :

) ( Reservoir .

( (Pump .

D-Tron Plus, H-Tron Plus, Cozmo, R- :

.1000

135


) soft cannula

( .

136
 .

137
 . 24

138
 .

AIC

,motivated ,

139


( 4 Inhaled

aerosol

) .(FDA

) (Exubera

).(Oralin

140


Oralin

141


142
 .

. FEV1

%70 .

( 5

143


2007

,Chitosan

( 6 ) ( Insulin

jet injectors

144


( 7

( 8

145
 ( 1

) (Glucagon

146


10-5

147


, .

148


) 40 100 .(3

149


) 600-300 100 .(3

, ,

150
 ,

) 50 /(

50-20 ) (%50

3-2 .

, -1

5 .

15

( 2

151
 60-30

, .

, , .

200

152
 IgG .

High titre IgG

200 .

, .

) ,

153
 ( lipodystrophy at

injection sites

atrophy

) (Hypertrophy

, .

( 3

( 4 .

154
 .

( 5

-1

155


. .

-2

8-2 )-36

46 (.

-3

-4

-5

-6 .

-7

156
 -8

157


) ( ,

158


.1

Insulin secretagogues )

( , ) ( .

.2 Insulin

sensitizer ) (,

) ( .

159
 .

.3 - Alph- glucosidase inhibitors

Sulfonylureas

160


30-20 .

10-7 .

161


2000

. 1 First Generation

,,

,.

.2 Second Generation

,,

162
 ,

(1 -

(2

163


(3

(University Group Diabetes Program 1970

. 1984 )

164
 (FDA

Tolbutamide

165


. )-6

8( , ( (Half-life 5-4.

) (

250 500.

166
 ) 500

( .

Acetohexamide

16-10 .

8-6 .

167
 250 500 .

1.5-0.25

, .

Tolazamide

) 14-12( , .

. 7

100 250 500

500

. 1000

168
 Chlorpropamide

. , %30-20

32 ,

100 250 .

250 .

500

169


7 6-8 4-5

32 12-14 10-16 6-8 ) (

20-60 ) ( ) ( ) (

) ( ) (

100-1000 250-1500 500-3000

100-500 1-2 1-2 2-3

1-2 ) (

170


, ,

) ( ,

) ( Glyburide

)(Glibenclamide

171
 .

) 3( ,

1.25 1.5 , 2.5 ,3 ,

5 ,.

2.5

. 10-5 ,

20 .

172


Glipizide

%90

, %10

. ) 4-2(

. 16-10

173
 15 -5

40 ,

20-15.

Glimperide

9-5

24-12 .

174


8 . ,

175


5-9 2-4 )( 3
12-24 10-16 12-24 )(

1-8 2.5-40 2.5-20 )(
1 1-2 1 /

176
 .

%30

, .

. .1

177
 .

.depolarization

.alloxan

.2 Glucagon

somatostatin

178
 ) (A cells . ,

,Streptozacin

.3 :

179


, .

. :

180
 .

, , ,

, , 1/10

Vasopressin

%1 .

181
 .

%3-1

)-(NSAIDS

, , -

182


Fluconazole

chloramphenicol

183


,Corticosteroids

) ,(beta blockers ) ,(niacin - )Retin-

(A

Thiazide

Furosemide

,Phenytoin

,Phenobarbital

184


185


100

186
187
 Meglitinides

Repaglinide

Natiglinide Mitiglinide

55 .

4-3

188


4-0.25 ) 16 (.

, ,

189


, ,

: Biguanides

Metformin

3 -1.5.

190


,,

) (.

191
 ,

)(LDL

(%8 ) ,(%28 ),(%16

).(%14

192


Polycystic

. ovaries

500

850 .

500 850

. 2550

500

. 500

2000

. .

193
 16-10 ,

500 , 500

2000 .

. , ,,

, .

%20

. %5-3

194


12 .

12

) (Lactic acidosis .

30000 %50 .

: ,

, ,

, , , .

195
 , Congestive heart

,failure ,.

, .

, ,

Alpha- glucosidase

inhibitors

Acarbose

)(

. )(

)(

) (

196
 .

" "

, .

" " .

1000

. "

"

197
 ,(duodenum ) ,(Jejunum ).(ileum

198


) (FDA

, , .

) (

A1C

100-25 ,

199


%2

, .

Thiazolidinediones

Rosiglitazon

Pioglitazone

200


) ,(%99

) 7( ,

) 150 , 24

( .

201
 .

.%30

, ,

202
 ) ) Troglitazone

, .

) , ,

, ( ,

203


.polycystic ovary) ( syndrome

) , , , ,

, , (.

204
 )( .

4-1

12-6 .

205


, 2-3


)
(,
1-2
) (.

1-2
, 1
1
1-2
1-2
1-2
1-2

3
3
1
,

)( 1-2

, 3
3

206


Vildagliptin

) .(incretin

207
 .

.( FDA

. .

208


, .

100-50 .

100

50

209


Exinatide

210


, ,

211


Glucagone , adrenaline

212


213


. 90-30

68

214
 .

215


, ,

. ,

, ,

216
 .

"" .

) (

217
 ,

200 .

metformin .valsartan

218


. ,

219


220


. . 1. ,

. , 1997 ,

. . 2.

. , , 2000 ,

. . 3. ,

. , 2003 ,

221
 4. - - - . -

, . 6

2004, , , .

ENGLISH REFERENCES

1. American Diabetes Association (ADA): Type-2 diabetes

in children and adolescents. Diabetes Care, 2000; 23: 381-

389

2. American Diabetes Association (ADA): Report of the

expert committee on the diagnosis and classification of

diabetes mellitus. Diabetes Care, 2001; 24 (Suppl.1): S5-

S20

222
3. Atkinson MA. and Eisenbarth GS: Type 1 diabetes: new

prospective on disease pathogenesis and treatment.

Lancent, 2001; 358(9277): 221-29

4. Berneyy, T; Biibler, L, Caulfield A, Toso, CB, Alejandro,

R, Cooper,D, Ricordi,C, Morel, PB.: Transplantation of

islets of Langerhans: new developments. Swiss Med Wkly

2002; 132: 671-680

5. Brajendra, K, and Srivastava, A.: Diabetes mellitus

complication and therapeutics.. Med Sci Monit, 2006;

12(7): RA130-147

6. Defronzo RA: Pathogenesis of type 2 diabetes: metabolic

and molecular implication for identifying diabetes genes.

Diabetes Rev, 1997; 5: 177-267

7. Frank, A. Deng S. Huang, X. et al: Transplantation for

Type 1 Diabetes: Comparison of Vascularized Whole-

Organ Pancreas With Isolated Pancreatic Islets. Annals of

Surgery .Volume 240, Number 4, October 2004; 631-643

223
8. Gale, E and Anderson, J.: Diabetes mellitus and other

disorders of metabolism. In, Kumar and Clark Clinical

medicine, 6th ed.,2005, vol. 19, 1110- 1112.

9. Kuzuya, T., Nakagawa, S., Satoh, J.: Report of the

committee on the classification and diagnostic criteria of

diabetes mellitus. Diabetes Research and Clinical

Practice, 2002: 55 (1): 65-85.

10. Osman, A.K. and AL-Nozha, M.M.: Risk factors of

coronary artery disease in different regions of Saudi

Arabia. Eastern Mediterranean Health J, 2000:6: 465-474.

11. Rosenbloom A, J 51 J, Young R, Winter W: Emerging

epidemic of Type 2 diabetes in youth. Diabetes Care,

2001; 22: 867-71

12. Rennert, O. and Gary, L.: Update on the genetics and

pathophysiology of type 1 diabetes mellitus. Pediatric

Annals, 1999: 28; 570-575.

13. Tumilehto J, Lindstrom J, Eriksson JG et al: Prevention of

type 2 diabetes mellitus by changes in lifestyle among

224
 subjects with impaired glucose tolerance. N Eng J Med,

2001; 344: 1343-50

14. World Health Organization (WHO): Definition, Diagnosis

and classification of diabetes mellitus and complications.

Part 1: Diagnosis and classification of diabetes mellitus.

Department of Non-communicable Disease Surveillance,

Geneva, 1999

15. Zhang C, Baffy G, Perret P et al: Uncoupling protein-2

negatively regulates insulin secretion and is a major link

between obesity, cell dysfunction, and type 2 Diabetes.

Cell, 2001; 105: 745-55

5 :

6
7
8
8
8
11
12

225
13 :
14
15
17
19 A1C

21

23 :
24
24
25
27
28

30
31
37
37
39 :
39 :
43
44
44
45

49 :

51
55
58
60
62
62
64
67
68

226
69
70
70
70
71
71
72
74
75

77 :
78
78
78
81
83
85
85
86
87
87
88

89
89
91
93
93
93
94
95
95
97
98
99
101
102
103
105
107
108
108

227
109
110
110
111
113
117
119
120 ) (
120
121

121
125
128
129
130
131
133
135

135
137
137
137
138
138
138
139
139
139
141
141 ) (
142
142
143
143
144
145
148
151
152
154

228
154
154
154
155
156
156
156
157
158
159
160
160
161
162
162
164
164
166
166
166
169
169
170
170
171
171

172 :
173
174
176 , ,

177
177
178

229
230